TCZ 162mg SC Q3W,TCZ 162mg SC Q2W,
BW <30kg (n=27)BW ≥30kg (n=25)
Model-computed steady state PK parameters, median [range]
 Cmin, μg/mL13.4 [0.2, 52.3]12.7 [0.2, 23.8]
 Cmax, μg/mL62.4 [39.4, 121.1]29.7 [7.6, 50.3]
 AUC12weeks, μg/mL×day2998 [1465, 7708]1933 [324, 3098]
Change from baseline to week 52a in PD markers and efficacy, median [range]; TCZ-naive pts
 IL-6, pg/mL27.3 [3.5, 173.9], n=1112.2 [−6.2, 30.9], n=9
 sIL-6R, ng/mL612.1 [399.4, 808.4], n=14429.3 [245.5, 585.6], n=11
 CRP, mg/L−1.3 [−17.0, 0.5], n=21−0.8 [−22.9, 0.0], n=12
 ESR, mm/h−11.0 [−40.0, 0.0], n=21−6.0 [−35.0, 0.0], n=12
 JADAS-71−16.8 [−40.3, −4.4], n=21−12.9 [−48.1, −2.3], n=12
  • aWeek 51 for Q3W group. AUC, area under the concentration curve; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IL-6, interleukin-6; sIL-6R, soluble IL-6 receptor.